Fucidin® Cream in the Treatment of Impetigo

A Phase IV Study Comparing Clinical and Bacteriological Efficacy of Fucidin® Cream With Fucidin® Cream Vehicle in the Treatment of Impetigo in Paediatric Patients

To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo in paediatric patients.

To assess the validity of in vitro susceptibility-testing of S. aureus to fusidic acid as a prediction of clinical and bacteriological outcome in impetigo patients treated with Fucidin® cream.

To investigate the genetic relationship between S. aureus-strains isolated from impetigo patients.

Inclusion Criteria:

• Patients with a clinical diagnosis of impetigo,
• Patients aged 2-11 years,
• Patients of either sex,
• Patients whose parent(s) has(ve) provided written consent, AND
• Patients with a severity score of 1 for at least one of the following signs: pustules/infected bullae, erythema and infiltration/induration.

Exclusion Criteria:

• Patients with other active inflammatory dermatitis at the area of impetigo,
• Patients with a temperature above 38.5 C rectally (or equivalent), OR
• Patients who have been administered topical or systemic Fucidin® or other antibacterial agents within the previous 4 weeks.